Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer

Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer

Experienced biotech finance leader with over 30 years’ experience in capital markets and strategy

Proven track record in fundraising, M&A and company transformation

Company is currently running two pivotal Phase 3 studies with nizubaglustat in GM1/ GM2 gangliosidoses and Niemann-Pick type C disease

Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer.